Ptc Therapeutics, INC Form 4 insider transactions

PTC Therapeutics Director Alethia Young was granted restricted stock units and stock options, aligning her interests with shareholders.

PTC Therapeutics Director David P. Southwell was granted 4,000 restricted stock units and 3,475 stock options under a pre-arranged plan.

PTC Therapeutics Director Stephanie Okey was granted 4,000 restricted stock units and 3,475 stock options, effective January 2, 2026.

PTC Therapeutics Director Allan Steven Jacobson acquired 4,000 restricted stock units and 3,475 stock options, increasing his beneficial ownership.

PTC Therapeutics Director Michael Schmertzler received 8,000 restricted stock units and 6,950 stock options, vesting over one year.

PTC Therapeutics' Chief Financial Officer, Pierre Gravier, was granted 20,000 restricted stock units and 50,000 stock options on January 2, 2026.

PTC Therapeutics CEO Matthew B. Klein received 63,000 restricted stock units and 157,500 stock options as part of his compensation package.

PTC Therapeutics Director Glenn Steele Jr. exercised options and sold shares under a 10b5-1 plan, while also receiving new restricted stock units and stock options.

PTC Therapeutics CEO Matthew B. Klein sold 8,089 shares of common stock at $76.64 per share to cover tax withholding obligations related to RSU vesting.

PTC Therapeutics' Chief Business Officer, Eric Pauwels, executed pre-planned transactions, exercising stock options and selling an equivalent number of common shares.

PTC Therapeutics' Chief Business Officer, Eric Pauwels, exercised stock options and subsequently sold the acquired shares, along with other common stock, under a pre-arranged 10b5-1 plan.

PTC Therapeutics Director Michael Schmertzler exercised 24,000 stock options at $30.86 per share, increasing his direct common stock holdings to 155,266 shares.

PTC Therapeutics Director Emma Reeve exercised stock options and sold an equal number of common shares under a pre-arranged 10b5-1 plan.

PTC Therapeutics CEO Matthew B. Klein reported the acquisition of restricted stock units and a subsequent sale to cover tax obligations.

PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, exercised stock options and subsequently sold common stock totaling 71,928 shares under a pre-arranged 10b5-1 plan.

PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, executed pre-planned sales of common stock totaling 35,572 shares on November 24, 2025, following option exercises.

PTC Therapeutics Director Allan Steven Jacobson executed pre-planned option exercises and subsequent sales of common stock shares on November 24 and 25, 2025.

PTC Therapeutics Director Emma Reeve exercised stock options and sold 10,000 shares of common stock for $79.50 per share under a pre-arranged 10b5-1 plan.

PTC Therapeutics Director Stephanie Okey reported a gift of 867 common shares to a charitable organization.

PTC Therapeutics' Executive VP and CLO, Mark Elliott Boulding, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

PTC Therapeutics Director Emma Reeve exercised stock options and immediately sold the acquired common stock on November 12, 2025, under a pre-arranged 10b5-1 plan.

PTC Therapeutics Director Emma Reeve executed a planned sale of common stock and exercised options on October 30, 2025, under a pre-arranged 10b5-1 plan.

A PTC Therapeutics executive exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 plan.

Emma Reeve, a Director at PTC Therapeutics, Inc., executed pre-planned transactions involving the exercise of stock options and subsequent sale of common stock on October 3, 2025.

PTC Therapeutics Director Allan Steven Jacobson exercised options and immediately sold 12,000 shares of common stock for $65.00 per share under a pre-arranged plan.

A PTC Therapeutics Executive VP and CLO exercised stock options and sold an equivalent number of shares under a pre-arranged 10b5-1 plan.

Neil Gregory Almstead, Chief Technical Ops Officer of PTC Therapeutics, executed transactions involving the sale and acquisition of common stock on October 3, 2025, according to a Form 4 filing.

PTC Therapeutics Director Emma Reeve executed a series of stock option exercises and subsequent sales of common stock totaling 15,705 shares under a Rule 10b5-1 plan on September 11, 2025.

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, exercised stock options and subsequently sold 47,249 shares of common stock for approximately $2.89 million.

PTC Therapeutics Director David P. Southwell exercised stock options and immediately sold 12,000 shares for a significant gain.